Moderna (MRNA) shares surged Thursday following positive results from a mid-stage trial for its experimental cancer vaccine. The trial found the vaccine, when used in combination with Merck's (MRK) immunotherapy Keytruda, significantly reduced the risk of death or relapse for patients with advanced melanoma skin cancer. "We are so happy for patients," Moderna CEO Stéphane Bancel told Yahoo Finance Live, noting the trial showed a roughly 50% survival rate, meaning one in two treated patients were able to live without a relapse. Bancel also highlighted other vaccines in Moderna's pipeline, including its treatment for Respiratory Syncytial Virus (RSV). For more expert insight and the latest market action, click here to watch this full episode of Yahoo Finance Live.